Theratechnologies Announces Financial Results for Second

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Theratechnologies Announces Financial Results for Second Quarter of 2016

MONTREAL, QUEBEC--(Marketwired - July 5, 2016) - Theratechnologies Inc. (Theratechnologies) (TSX:TH) today announced its financial results for the second quarter ended May 31, 2016.

Second quarter 2016 financial highlights

  • Net sales of $9,026,000
  • Adjusted EBITDA of $1,362,000
  • Net loss of $498,000 or 0.01 per share
  • Liquidities of $9,239,000

"We are pleased with the revenue generated by EGRIFTA ® in the second quarter. Indeed, revenues in U.S. dollars grew by 11 percent quarter-over-quarter and by 24 percent when compared to the same quarter last year," said Luc Tanguay, President and CEO, Theratechnologies Inc.

"In addition, in the second quarter, we announced the agreement for the commercialization of ibalizumab in the United States and Canada. Shortly thereafter, we released preliminary Phase III clinical trial data showing that 82.5% of enrolled patients had reached the primary endpoint. These results gave us even more reasons to be very excited about this breakthrough treatment addressing multi-drug resistant HIV infection. If approved, it could start generating revenues as early as next year," added Luc Tanguay.

Revised guidance

While EGRIFTA ® sales are growing, the current rate of growth is lower than previously expected. In addition, the recent strengthening of the CAD versus the USD has negatively affected revenue guidance reported in CAD by an amount of close to $3,000,000. For the twelve months ending November 30, 2016, we now expect that net sales of EGRIFTA ® will be in the range of $36,000,000 to $37,000,000 (previously $46,000,000 to $49,000,000). Our expectations for Adjusted EBITDA in Fiscal 2016 are now in the range of $5,000,000 to $6,000,000 (previously $9,000,000 to $11,000,000). For the balance of fiscal 2016, we have assumed an average exchange rate of USD 1 = CAD 1.30. See "Non-IFRS Financial Measures" below.

Second Quarter Financial Results

The financial results presented in this press release are taken from the Company's Management's Discussion and Analysis, or MD&A, and unaudited consolidated financial statements for the period ended May 31, 2016, which have been prepared in accordance with International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Board, or IASB. The MD&A for the second quarter ended May 31, 2016 and the unaudited consolidated financial statements can be found at www.theratech.com and www.sedar.com . Unless specified otherwise, all amounts in this press release are in Canadian dollars and all capitalized terms have the meaning ascribed thereto in our MD&A. As used herein, EGRIFTA ® refers to tesamorelin for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. EGRIFTA ® is our registered trademark.

Consolidated revenue for the three- and six-month periods ended May 31, 2016 was $9,027,000 and $17,770,000 compared to $7,280,000 and $11,851,000 in the comparable periods of fiscal 2015.

Revenue generated from net sales in the three- and six-month periods ended May 31, 2016 was $9,026,000 and $17,767,000 compared to $7,076,000 and $11,643,000 in the comparable periods of fiscal 2015, reflecting increased volumes and a price increase that took effect in January 2016.

In the three months ended May 31, 2015, we received an upfront payment of $200,000 from AOP Orphan Pharmaceuticals AG, or AOP, our commercial partner in Europe.

For the three- and six-month periods ended May 31, 2016, the cost of goods sold was $1,017,000 and $2,072,000 compared to $937,000 and $1,578,000 in the comparable periods of fiscal 2015. Royalty expense in the three- and six- month periods ended May 31, 2016 was $666,000 and $1,014,000. Royalties on EGRIFTA ® sales became payable effective January 1, 2016 and thereafter under the terms of the EMD Serono Termination Agreement.

R&D expenses R&D expenses in the three- and six-month periods ended May 31, 2016 amounted to $2,134,000 and $4,018,000 compared to $1,388,000 and $2,508,000 in the comparable periods of fiscal 2015. Most of the year-over-year increase is the result of increased spending on medical affairs in support of our goal of increasing the EGRIFTA ® patient base. Medical affairs is largely medical education programs involving opinion-leading physicians and nurses who work with the HIV-infected population to build scientific awareness about EGRIFTA ® and its therapeutic benefits. R&D expenses also include costs associated with our two Phase 4 clinical trials, which amounted to $638,000 and $1,324,000 in the three- and six-month periods ended May 31, 2016 compared to $1,014,000 and $1,680,000 in the comparable periods of fiscal 2015. Other components of R&D expenses are regulatory affairs and quality assurance.

Because most of our R&D expenses are incurred in the United States, part of the year-over-year variation in R&D expenses is attributable to changes in the value of the CAD versus the USD.

Selling and market development expenses in the three- and six-month periods ended May 31, 2016 amounted to $3,333,000 and $7,236,000 compared to $2,537,000 and $5,053,000 in the comparable periods of fiscal 2015. The increase is principally due to growth in our business and an intensified marketing effort, notably promotional campaigns aimed at increasing awareness of EGRIFTA ® and its therapeutic benefits within the HIV community.

Selling and market development expenses also include the amortization of the intangible asset value established for the EGRIFTA ® commercialization rights. In the three- and six-month periods ended May 31, 2016, this amortization expense amounted to $491,000 and $1,016,000 compared to $468,000 and $923,000 in the comparable periods of fiscal 2015.

Because most of our Selling and Market Development expenses are incurred in the United States, part of the year-over-year variation in selling and market development expenses is attributable to changes in the value of the CAD versus the USD.

General and administrative expenses in the three- and six-month periods ended May 31, 2016 amounted to $1,109,000 and $2,192,000, up only slightly from the $1,013,000 and 2,033,000 reported in the comparable periods of fiscal 2015.

Finance income for the three- and six-month periods ended May 31, 2016 was $31,000 and $59,000 compared to nil and $258,000 in the comparable periods of fiscal 2015. Finance income in the first six months of 2015 included a gain of $188,000 on the renegotiation of the long-term obligation owed to EMD Serono, or Long-term Obligation.

Finance costs for the three- and six-month periods ended May 31, 2016 were $1,323,000 and $2,008,000 compared to $606,000 and $1,042,000 in the comparable periods of fiscal 2015. These costs are almost entirely non-cash items. Finance costs in the second quarter of 2016 included a loss of $1,035,000 related to an increase in the fair value of outstanding warrants (see note 10 of the Interim Consolidated Financial Statements). Finance costs for the three- and six-month periods ended May 31, 2016 also included $507,000 and $1,101,000 of accretion expense on the Long-term obligation, compared to $635,000 and $1,209,000 in the comparable periods of fiscal 2015.

The adjusted EBITDA for the three- and six- month periods ended May 31, 2016 was $1,362,000 and $2,464,000 compared to $1,885,000 and $1,633,000 in the comparable periods of fiscal 2015. Adjusted EBITDA in fiscal 2016 is being negatively affected by the impact of EMD Serono royalties on earnings, which commenced on January 1, 2016. For a reconciliation of net loss and Adjusted EBITDA see "Non-IFRS Financial Measures" below.

Taking into account the revenue and expense variations described above, in particular the loss of $1,035,000 on the increase in fair value of outstanding warrants and the commencement of EMD Serono royalties on January 1, 2016, we recorded a net loss of $498,000 or $(0.01) per share in the three months ended May 31, 2016 compared to a net profit of $818,000 or $0.01 per share in the comparable period of fiscal 2015. In the six-month period ended May 31, 2016 the net loss was $651,000 or $(0.01) per share compared to a net loss of $96,000 or $0.00 per share in the comparable period of fiscal 2015.

In the three-month period ended May 31, 2016, operating activities generated cash flow of $233,000, compared to $1,106,000 in the comparable period of fiscal 2015. In the second quarter of fiscal 2016, changes in operating assets and liabilities reduced cash flow by $1,175,000. These included an increase in trade and other receivables and inventories, partially offset by increased accounts payable and accrued liabilities, and lower prepaid expenses.

A major use of cash in the second quarter of fiscal 2016 was a $5,196,000 payment against the Long-term Obligation; while the exercise of stock options generated $220,000 of cash in the period.

In accordance with the terms of the Ibalizumab Agreement, $1,491,000 (USD $1,000,000 plus related expenses) was paid in the second quarter of fiscal 2016 (see note 7 of the Interim Consolidated Financial Statements).

As at May 31, 2016, cash, cash equivalents and bonds amounted to $9,239,000 compared to $15,350,000 at November 30, 2015.

Non-IFRS Financial Measures

Reconciliation of net profit or loss to adjusted earnings before interest, taxes, depreciation and amortization (Adjusted EBITDA)

Adjusted EBITDA is a non-IFRS financial measure. A reconciliation of the Adjusted EBITDA is presented in the table below. We use adjusted financial measures to assess our operating performance. Securities regulations require that companies caution readers that earnings and other measures adjusted to a basis other than IFRS do not have standardized meanings and are unlikely to be comparable to similar measures used by other companies. Accordingly, they should not be considered in isolation. We use Adjusted EBITDA to measure operating performance from one period to the next without the variation caused by certain adjustments that could potentially distort the analysis of trends in our business, and because we believe it provides meaningful information on our financial condition and operating results.

We obtain our Consolidated Adjusted EBITDA measurement by adding to net profit or loss, finance income and costs, depreciation and amortization, income taxes, as well as federal investment ARC credits recorded in 2014. We also exclude the effects of certain non-monetary transactions recorded, such as share-based compensation for stock option plan and write down of inventories, for our Adjusted EBITDA calculation. We believe it is useful to exclude these items as they are either non-cash expenses, items that cannot be influenced by management in the short term, or items that do not impact core operating performance. Excluding these items does not imply they are necessarily nonrecurring. Share-based compensation costs are a component of employee remuneration and can vary significantly with changes in the market price of the company's shares. In addition, other items that do not impact core operating performance of the company may vary significantly from one period to another. As such, Adjusted EBITDA provides improved continuity with respect to the comparison of our operating results over a period of time. Our method for calculating Adjusted EBITDA may differ from that used by other companies.

Adjusted EBITDA

Three-month periods ended May 31, Six-month periods ended May 31,
2016 2015 2016 2015
$ $ $ $
Net profit (loss) (498 ) 818 (651 ) (96 )
Add (deduct):
Depreciation and amortization 498 470 1,026 929
Finance costs 1,323 606 2,008 1,042
Finance income (31 ) 0 (59 ) (258 )
Share-based compensation for stock option plan 96 25 166 40
Income tax expenses -- 0 -- 10
Write-down of inventories (26 ) (34 ) (26 ) (34 )
Adjusted EBITDA 1,362 1,885 2,464 1,633

Conference Call Details

A conference call will be held tomorrow, July 6, 2016 at 8:30 a.m. (ET) to discuss the results. The call will be hosted by Luc Tanguay, President and Chief Executive Officer. The conference call will be open to questions from financial analysts. Media and other interested individuals are invited to participate in the call on a "listen-only" basis.

The conference call can be accessed by dialling 1-877-223-4471 (North America) or 1-647-788-4922 (International). The conference call will also be accessible via webcast at http://www.gowebcasting.com/7566 . Audio replay of the conference call will be available from July 7, 2016 11:30 a.m. and until July 19, 2016, by dialling 1-800-585-8367 (North America) or 1-416-621-4642 (International) and by entering the playback code 10732812.

About Theratechnologies

Theratechnologies (TSX:TH) is a specialty pharmaceutical company addressing unmet medical needs to promote healthy ageing and improved quality of life among HIV patients. Further information about Theratechnologies is available on the Company's website at www.theratech.com and on SEDAR at www.sedar.com .

Forward-Looking Information

This press release contains forward-looking statements and forward-looking information, or, collectively, forward-looking statements, within the meaning of applicable securities laws, that are based on our management's belief and assumptions and on information currently available to our management. You can identify forward-looking statements by terms such as "may", "will", "should", "could", "would", "outlook", "believe", "plan", "envisage", "anticipate", "expect" and "estimate", or the negatives of these terms, or variations of them. The forward-looking statements contained in this press release include, but are not limited to, statements regarding the approval and commercialization of ibalizumab as a treatment and our anticipated revenue and Adjusted EBITDA for Fiscal 2016 .

Forward-looking statements are based upon a number of assumptions and include, but are not limited to, the following: our marketing campaign in the United States will allow us to increase the patient base for EGRIFTA ® and to thereby grow our sales, revenues and achieve positive earnings, we will have continuous supply of EGRIFTA ® , the ongoing Phase III clinical trial for ibalizumab will generate positive results and Ibalizumab will be approved by the United States Food and Drug Administration, or FDA, the FDA will not issue any order or decision having the effect of suspending the commercialization of EGRIFTA ® in the United States, the relationships with our commercial partners and third-party suppliers will be conflict-free and no unforeseen event will result in unplanned expenditures.

Forward-looking statements are subject to a variety of risks and uncertainties, many of which are beyond our control that could cause our actual results to differ materially from those that are disclosed in or implied by the forward-looking statements contained in this press release. These risks and uncertainties include, but are not limited to, the risk that sales of EGRIFTA ® in the United States decrease, the risk that we are unable to supply EGRIFTA ® in the United States, in Canada and to our commercial partners in Europe, Mexico and South Korea because of increasing sales or because of manufacturing issues which would deplete our current inventory, the risk that EGRIFTA ® is subject to a recall, the risk that Phase III results from the ongoing clinical trial for ibalizumab are not conclusive, the risk that the FDA does not approve Ibalizumab and the risk that our operating expenses are materially adversely affected by unforeseen events.

We refer potential investors to the "Risks Factors" section of our Annual Information Form dated February 24, 2016 available at www.sedar.com . The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward-looking statements. Forward-looking statements reflect current expectations regarding future events and speak only as of the date of this press release and represent our expectations as of that date.

We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise, except as may be required by applicable law.

Denis Boucher EXOCET Public Relations inc. 514-913-1957
Scroll down for more posts ▼

Top 10 Most Recent News Articles

InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 343

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 466

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 223

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 335

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 251

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 241

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 416

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 129

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 246

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 185

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading

Top 5 Most Recently Viewed Articles

Geotab's Vision for Addressing Youth Unemployment Through Internships

Updated Category News Views 169

Geotab's Commitment to Future Workforce Development As Geotab Inc. celebrates its remarkable 25th anniversary, the company is taking bold steps to enhance internship opportunities for young graduates entering an increasingly competitive job market. With youth unemployment rates rising in North America, organizations like Geotab are not only addressing a pressing social...

Continue Reading
Joaquín de Valenzuela Joins nCino as EMEA Managing Director

Updated Category News Views 90

Joaquín de Valenzuela Takes the Helm at nCino for EMEA nCino, Inc. (NASDAQ: NCNO), a leader in intelligent banking solutions, is proud to announce the appointment of Joaquín de Valenzuela as the Managing Director for the EMEA region. This significant hire underscores the company's dedication to bolstering its growth trajectory and expanding its influence across the...

Continue Reading
Aya Gold & Silver Unveils Stunning Silver Drilling Results

Updated Category News Views 123

Aya Gold & Silver Reports New Silver Drilling Success Aya Gold & Silver Inc. (TSX: AYA; OTCQX: AYASF) is excited to share outstanding silver drill results from its ongoing exploration at the Zgounder Silver Mine. The results not only highlight high-quality silver finds but also identify several promising new targets in the Zgounder Regional area. Drilling Highlights and...

Continue Reading
Nvidia's Deep Roots in China's Tech Landscape Drive AI Success

Updated Category News Views 278

Nvidia's Deep Roots in China's Tech Landscape Drive AI Success Nvidia Corp. CEO Jensen Huang recently highlighted the significant impact of China’s technology ecosystem on Nvidia’s growth during a keynote address at a major university event. His reflections underline a robust relationship spanning over 25 years, which has been pivotal in shaping Nvidia into a leading...

Continue Reading
Aalberts N.V. Achieves Strategic Growth Despite Market Challenges

Updated Category News Views 314

Aalberts N.V. Reports First Quarter Results In the latest financial report, Aalberts N.V. showcased its first quarter outcomes, revealing revenues of EUR 778.3 million. This figure marks a 3.3% decline in organic revenue compared to the same period last year, pointing to ongoing challenges within the market. Operational Performance and Margin Insights The company's EBITA...

Continue Reading